

|  |  |
| --- | --- |
| **Examination question paper:** | **May 2025** |

|  |  |
| --- | --- |
| **Module code:**  **Component number:** | **CY6065**  **002** |
| **Module title:** | **Neuropharmacology** |
| **Module leader:** | **Dr Chris Bax** |

|  |  |
| --- | --- |
| **Date:** | **May 2025** |
| **Duration:** | **1 Hour 30 Minutes** |

|  |  |
| --- | --- |
| **Exam type:** | Part seen/Part unseen, Closed |
| **Materials supplied:** | **None** |
| **Materials permitted:** | **None** |
| **Warning:** | **Candidates are warned that possession of unauthorised materials in an examination is a serious assessment offence.** |

|  |  |
| --- | --- |
| **Instructions to candidates:** | **Section A is unseen; write your answers on this paper.**  **Section B is seen; write your answer in the answer booklet provided.**  **You are advised to spend 50% of your time on Section A, and 50% on Section B.**  **Maximum marks possible: 100.** |
|  |  |
|  | **Do not turn page over until instructed** |

© London Metropolitan University

### 

SECTION B (Seen)

Maximum marks for Section B: 50

Answer **one** question in the booklet provided.

17. a) Account for the roles of (i) amyloid precursor protein, and (ii) tau proteins in

Alzheimer’s disease (AD).

**20 marks**

b) What are the current treatment strategies employed in treating AD patients?

**30 marks**

18.Critically evaluate Schildkraut’s hypothesis of clinical depression in the light of recent developments in the understanding of the disorder.

**50 marks**

19. a) With reference to drug abuse, explain the pharmacological effects of

opioids on the central nervous system.

**40 marks**

b) How can dependence on opioids be treated?

**10 marks**

**END OF PAPER**